Curate Biosciences

Curate Biosciences develops a proprietary microfluidic-based cell processing system that enables virtually lossless, gentle separation of leukocytes from apheresis or culture samples. This system addresses key bottlenecks in the manufacturing of next-generation cell and gene therapies—especially CAR-T—by providing cleaner starting material faster, reducing vein-to-vein time, improving yields of healthy cells, and potentially enhancing clinical outcomes. Their technology has been validated by over ten partners including leading academic centers such as City of Hope integrating it into investigational CAR-T workflows. The company’s products are commercially available to biopharma companies and CDMOs supporting advanced therapy development.